Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Erlander

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
The Oncologist|April 30, 2010
Molecular profiling in unknown primary cancer: accuracy of tissue of origin predictionF Anthony Greco, David R Spigel, Denise A Yardley, et al.
The Journal of Molecular Diagnostics : JMD|January 5, 2013
Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumorsLawrence M Weiss, Peiguo Chu, Brock E Schroeder, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case seriesNishan Tchekmedyian, Raja Mudad, Fernando F Blanco, et al.
Breast Cancer Research : BCR|October 18, 2011
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancerRachel C Jankowitz, Kristine Cooper, Mark G Erlander, et al.
Journal of Medical Economics|April 3, 2014
Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancerTanya G K Bentley, Brock E Schroeder, Catherine A Schnabel, et al.
The Journal of Clinical Investigation|June 17, 2004
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruliKarin S Peterson, Jing-Feng Huang, Jessica Zhu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 13, 2013
A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumorsSarah E Kerr, Catherine A Schnabel, Peggy S Sullivan, et al.
European Journal of Pharmacology|February 5, 2020
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α<sub>1</sub>-blockersXiaolong Wang, Bingsheng Li, Anna Ciotkowska, et al.
Breast Cancer Research : BCR|March 19, 2013
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive diseaseLaurel A Habel, Lori C Sakoda, Ninah Achacoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
The Oncologist|April 30, 2010
Molecular profiling in unknown primary cancer: accuracy of tissue of origin predictionF Anthony Greco, David R Spigel, Denise A Yardley, et al.
The Journal of Molecular Diagnostics : JMD|January 5, 2013
Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumorsLawrence M Weiss, Peiguo Chu, Brock E Schroeder, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case seriesNishan Tchekmedyian, Raja Mudad, Fernando F Blanco, et al.
Breast Cancer Research : BCR|October 18, 2011
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancerRachel C Jankowitz, Kristine Cooper, Mark G Erlander, et al.
Journal of Medical Economics|April 3, 2014
Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancerTanya G K Bentley, Brock E Schroeder, Catherine A Schnabel, et al.
The Journal of Clinical Investigation|June 17, 2004
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruliKarin S Peterson, Jing-Feng Huang, Jessica Zhu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 13, 2013
A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumorsSarah E Kerr, Catherine A Schnabel, Peggy S Sullivan, et al.
European Journal of Pharmacology|February 5, 2020
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α<sub>1</sub>-blockersXiaolong Wang, Bingsheng Li, Anna Ciotkowska, et al.
Breast Cancer Research : BCR|March 19, 2013
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive diseaseLaurel A Habel, Lori C Sakoda, Ninah Achacoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Pageof 5